VEGF Trap-Eye: one year results

Article

VEGF Trap-Eye, Regeneron's treatment for wet age-related macular degeneration (AMD), has demonstrated improved visual acuity (VA) and reduced biological markers of neovascular disease at one year of follow-up, according to final Phase II results presented at this year's Scientific Meeting of the Retina Society, held September 26–28 in Scottsdale, Arizona, US.

VEGF Trap-Eye, Regeneron's treatment for wet age-related macular degeneration (AMD), has demonstrated improved visual acuity (VA) and reduced biological markers of neovascular disease at one year of follow-up, according to final Phase II results presented at this year's Scientific Meeting of the Retina Society, held September 26–28 in Scottsdale, Arizona, US.

Study subjects (n=157) have been receiving the drug - initially on a fixed-dose and then on a PRN (as-needed) dosing schedule - for 52 weeks. The double-masked, prospective, randomized, multicentre Phase II extension study monitored safety, retinal thickness and vision gain. Subjects were separated into groups receiving doses of 0.5 mg at weeks 0, four, eight and 12 (Group A) and doses of 2.0 mg at weeks 0, four, eight and 12 (Group B). After week 12, patients received VEGF Trap-Eye on an as-needed (PRN) dosing schedule.

Patients in Group A achieved a mean VA improvement of 9.0 letters over baseline at one year; Group B, 5.4 letters. In Group A, the proportion of patients with ≥20/40 vision increased from 23% at baseline to 45% at one year; in Group B, this improvement was from 16% to 47%. During the 40-week PRN dosing period, patients in Group A received a mean of 1.6 additional injections; Group B required an extra 2.5 injections. Retinal thickness increase was 143 µm for Group A and 125 µm for Group B. These improvements were achieved mostly during the initial 12-week, fixed-dose portion of the trial, and were maintained throughout the 52 week period. In addition to this, the choroidal neovascular membrane (CNV) reduced by 3.41 mm and 1.42 mm at week 48 for Groups A and B, respectively. Although VEGF Trap-Eye was well tolerated, intravitreal injection-related complications were present, and a single incidence of culture-negative endophthalmitis/uveitis (unrelated to the drug) was reported.

The two ongoing Phase III trials of the VEGF Trap-Eye, initiated in August 2007, compare VEGF Trap-Eye with Lucentis (ranibizumab; Novartis). The trials are being conducted in the US, Canada, Europe, Asia Pacific, Japan and Latin America, and are currently enrolling patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.